TPG and Blackstone Join Forces for Bausch + Lomb Acquisition
Private equity giants TPG and Blackstone are collaborating in their pursuit to acquire the renowned eye care company Bausch + Lomb (NYSE: BLCO). Their efforts signal a growing momentum in the market, as reported by sources familiar with the matter.
The Sale Process Unfolds
Recently, Bausch + Lomb announced that it was actively considering the sale of its business. This move comes as part of a strategic effort to address the concerns of creditors, primarily Apollo Global Management Inc (NYSE: APO), regarding its separation from the parent organization, Bausch Health Companies (NYSE: BHC).
Debt Relief Strategy
The decision to explore a sale is closely linked to Bausch Health's strategy to mitigate its substantial debt burden, which has reached a staggering $21 billion. Approximately one-third of this debt is due by 2027, prompting the company to take actionable steps, such as spinning off Bausch + Lomb.
Potential Buyers Positioning
If TPG and Blackstone’s bid proves successful, it could become one of the largest private equity buyouts within the year. Bausch + Lomb’s total enterprise value, inclusive of its debts, currently stands at $11.5 billion. With other potential bidders dropping out, TPG and Blackstone have positioned themselves as the leading candidates for the acquisition.
Valuation Insights
Market expectations for the acquisition process suggest a valuation for Bausch + Lomb in the range of $13 billion to $14 billion. This would translate to a per-share price of up to $25, an indication of the strong interest in this premium eye care brand.
Goldman Sachs Leading the Charge
Bausch + Lomb has enlisted Goldman Sachs to spearhead the sales process. This initiative aims to resolve ongoing tensions between Bausch Health's shareholders and its creditors, ensuring a smooth transition in the ownership structure if the deal is finalized.
Brent Saunders: A Proven Leader
Brent Saunders, the CEO of Bausch + Lomb, is well-known in the industry for his pivotal role in orchestrating Allergan’s monumental $63 billion sale to AbbVie Inc (NYSE: ABBV). Although formal bids are anticipated by the end of this month, it’s crucial to note that a finalized agreement is not guaranteed.
Shareholder Perspectives
Among Bausch Health’s notable shareholders, figures like Carl Icahn and John Paulson through Paulson & Co. have fully backed the spin-off. They perceive potential value in owning a more significant stake in the lucrative eye care division, which is expected to enhance their portfolios.
Challenges for Bausch Health
Bausch Health is grappling with challenges associated with its leading drug, Xifaxan, which is set to lose patent protection by 2029. This development adds a layer of urgency to their strategic maneuvers in the market.
Current Market Performance
As of the latest premarket data, Bausch + Lomb's stock has rallied by 10.7%, reaching $21.55. This surge reflects the company's favorable sentiment amidst the speculation regarding its potential acquisition.
Frequently Asked Questions
What companies are interested in acquiring Bausch + Lomb?
TPG and Blackstone are currently the primary contenders in the acquisition of Bausch + Lomb.
What is the current valuation range for Bausch + Lomb?
The expected valuation for Bausch + Lomb during the sales process is between $13 billion and $14 billion.
Who is leading the sale process for Bausch + Lomb?
Goldman Sachs is overseeing the sale process for Bausch + Lomb, helping navigate the negotiations and strategic discussions.
What challenges does Bausch Health face?
Bausch Health is facing significant challenges due to the impending patent expiration of its leading drug, Xifaxan, by 2029.
How has the stock price of Bausch + Lomb responded recently?
The stock price of Bausch + Lomb has seen a positive increase of 10.7%, now trading at $21.55 in the premarket session.
